BR112022009273A2 - Imunoglobulinas modificadas para direcionar depósitos amiloides - Google Patents

Imunoglobulinas modificadas para direcionar depósitos amiloides

Info

Publication number
BR112022009273A2
BR112022009273A2 BR112022009273A BR112022009273A BR112022009273A2 BR 112022009273 A2 BR112022009273 A2 BR 112022009273A2 BR 112022009273 A BR112022009273 A BR 112022009273A BR 112022009273 A BR112022009273 A BR 112022009273A BR 112022009273 A2 BR112022009273 A2 BR 112022009273A2
Authority
BR
Brazil
Prior art keywords
modified
antibody
immunoglobulins
amyloid
amyloid deposits
Prior art date
Application number
BR112022009273A
Other languages
English (en)
Portuguese (pt)
Inventor
S Wall Jonathan
S Foster James
Guthrie Spencer
Original Assignee
Univ Tennessee Res Found
Attralus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found, Attralus Inc filed Critical Univ Tennessee Res Found
Publication of BR112022009273A2 publication Critical patent/BR112022009273A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
BR112022009273A 2019-11-15 2020-11-13 Imunoglobulinas modificadas para direcionar depósitos amiloides BR112022009273A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962936002P 2019-11-15 2019-11-15
US202063074912P 2020-09-04 2020-09-04
PCT/US2020/060596 WO2021097360A1 (en) 2019-11-15 2020-11-13 Modified immunoglobulins for targeting amyloid deposits

Publications (1)

Publication Number Publication Date
BR112022009273A2 true BR112022009273A2 (pt) 2022-10-04

Family

ID=75912899

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009273A BR112022009273A2 (pt) 2019-11-15 2020-11-13 Imunoglobulinas modificadas para direcionar depósitos amiloides

Country Status (11)

Country Link
US (5) US20220411489A1 (https=)
EP (1) EP4058479A4 (https=)
JP (2) JP7722990B2 (https=)
KR (1) KR20220113950A (https=)
CN (1) CN115298214A (https=)
AU (1) AU2020385183A1 (https=)
BR (1) BR112022009273A2 (https=)
CA (1) CA3158206A1 (https=)
IL (1) IL292903B2 (https=)
MX (1) MX2022005850A (https=)
WO (1) WO2021097360A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
WO2022120378A1 (en) * 2020-12-04 2022-06-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
JP2024519488A (ja) * 2021-05-05 2024-05-14 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド疾患を治療するためのペプチド－ｆｃ融合体
JP2024521082A (ja) * 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体－ペプチド融合タンパク質
AU2022346750A1 (en) * 2021-09-14 2024-04-11 Caelum Biosciences, Inc. Method of treating multiple myeloma
EP4430071A4 (en) * 2021-11-12 2026-01-14 Adrx Inc ANTIBODIES BINDING TO THE TRANSTHYRETIN (TTR) MONOMER
US20250298033A1 (en) * 2022-05-11 2025-09-25 Alexion Pharmaceuticals, Inc. High sensitivity biotinylated peptide binding elisa assay
US20260070962A1 (en) * 2022-09-02 2026-03-12 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
AU2024339036A1 (en) 2023-09-07 2026-03-12 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2025212955A1 (en) 2024-04-05 2025-10-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases
WO2026055521A1 (en) * 2024-09-06 2026-03-12 University Of Tennessee Research Foundation Antibody-peptide fusion proteins for treating amyloid disorders

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
EP0733070A1 (en) * 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
DE69942274D1 (de) * 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
JP5137400B2 (ja) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
DE602006008460D1 (de) 2005-06-17 2009-09-24 Ca Nat Research Council NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
EP2125893A2 (en) * 2007-01-23 2009-12-02 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
DK2237803T3 (en) * 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US20140079691A1 (en) 2012-09-20 2014-03-20 Anaptysbio, Inc. Thermostable antibody framework regions
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
US10213506B2 (en) 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
KR20240095466A (ko) 2017-01-30 2024-06-25 내션얼 리서치 카운슬 오브 캐나다 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도
RU2746325C1 (ru) * 2017-06-29 2021-04-12 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Химерные антитела для лечения заболеваний, характеризующихся отложением амилоида
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
IL279399B1 (en) 2018-06-14 2026-04-01 Bioatla Llc Multispecific antibody templates
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
EP4058479A4 (en) 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
JP2024521082A (ja) 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体－ペプチド融合タンパク質

Also Published As

Publication number Publication date
US20240294620A1 (en) 2024-09-05
CN115298214A (zh) 2022-11-04
US12264195B2 (en) 2025-04-01
IL292903B2 (en) 2026-04-01
US20240294621A1 (en) 2024-09-05
CA3158206A1 (en) 2021-05-20
IL292903A (en) 2022-07-01
JP2025134876A (ja) 2025-09-17
JP7722990B2 (ja) 2025-08-13
IL292903B1 (en) 2025-12-01
US12157765B2 (en) 2024-12-03
US20230265178A1 (en) 2023-08-24
EP4058479A4 (en) 2024-02-28
JP2023502968A (ja) 2023-01-26
AU2020385183A1 (en) 2022-05-26
US20250368729A1 (en) 2025-12-04
MX2022005850A (es) 2022-08-15
US20220411489A1 (en) 2022-12-29
WO2021097360A1 (en) 2021-05-20
US12030934B2 (en) 2024-07-09
KR20220113950A (ko) 2022-08-17
EP4058479A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
BR112022009273A2 (pt) Imunoglobulinas modificadas para direcionar depósitos amiloides
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
CO2020014773A2 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
AR106754A1 (es) Proteínas de unión a la proteína de muerte celular programada (pd1) y/o gen de activación de linfocitos 3 (lag3)
PE20090831A1 (es) Anticuerpo monoclonal
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
BR112016030686A2 (pt) anticorpos anti tau humanizados
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
PE20211293A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MX2014003357A (es) Terapia basada en proteina y diagnostico de patalogia mediada por tau en la enfermedad de alzheimer.
CR20120027A (es) Polipeptidos y metodo de tratamiento
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
MX2023013050A (es) Proteinas de fusion anticuerpo-peptido para el tratamiento de trastornos amiloides.
CL2020002621A1 (es) Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
JOP20210166A1 (ar) علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r
JOP20210168A1 (ar) أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
EA202091577A1 (ru) Глюкуронилирование в качестве новой кислотной посттрансляционной модификации терапевтических моноклональных антител
EA201892427A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИ-FcRn АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ
AU2018281871A1 (en) Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
PE20190633A1 (es) Anticuerpos anti-gm-csf y usos de los mismos